U.S. markets closed
  • S&P 500

    4,395.64
    +41.45 (+0.95%)
     
  • Dow 30

    34,258.32
    +338.48 (+1.00%)
     
  • Nasdaq

    14,896.85
    +150.45 (+1.02%)
     
  • Russell 2000

    2,218.56
    +32.38 (+1.48%)
     
  • Crude Oil

    72.00
    -0.23 (-0.32%)
     
  • Gold

    1,768.40
    -10.40 (-0.58%)
     
  • Silver

    22.69
    -0.22 (-0.95%)
     
  • EUR/USD

    1.1697
    -0.0033 (-0.28%)
     
  • 10-Yr Bond

    1.3360
    +0.0120 (+0.91%)
     
  • GBP/USD

    1.3622
    -0.0043 (-0.31%)
     
  • USD/JPY

    109.7990
    +0.5790 (+0.53%)
     
  • BTC-USD

    43,408.79
    +2,099.83 (+5.08%)
     
  • CMC Crypto 200

    1,089.55
    +49.07 (+4.72%)
     
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Isoray to Present at the H.C. Wainwright BioConnect 2021 Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

RICHLAND, Wash., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator powering expanding treatment options throughout the body, today announced that Chief Executive Officer Lori Woods will present at the H.C. Wainwright BioConnect 2021 Conference. The virtual conference will be held January 11-14, 2021.

The on-demand presentation will be available on Isoray’s Investor Relations section of the Company’s website at https://isoray.com/investors/presentations/ at 6:00 a.m. EDT on Monday, January 11, 2021. It will remain available on the website for 90 days.

About Isoray
Isoray, Inc., through its subsidiary, Isoray Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Follow us on LinkedIn and Twitter. Join us on Facebook.

CONTACT: Contact: Investor Relations: Mark Levin (501) 255-1910 Media and Public Relations: Sharon Schultz (302) 539-3747